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Contagious caprine pleuropneumonia (CCPP) is a severe infectious disease affecting goats and wildlife, characterized by
acute unilateral lesions of pleurisy and pneumonia. The distribution of CCPP is still not well known although its presence in
China and Tajikistan has recently been demonstrated. However there are very few studies concerning its real prevalence and
economic impact. In countries where it exists, control strategies can rely on vaccination which is performed with inactivated
adjuvanted vaccines. Although these vaccines have been shown to be effective, their production is very costly as the CCPP
causative agent, Mycoplasma capricolum subsp. capripneumoniae (Mccp) is highly fastidious to grow in vitro. In addition, the
procedures to control the quality of these vaccines are not entirely satisfactory as there was no tool to specifically evaluate the
immunogenicity of these products. Within the framework of the VACNADA project, it was decided to re-formulate and validate
a specific competition ELISA with two main goals: allowing a quality control of CCPP vaccine batches and detecting
specifically CCPP outbreaks in countries where vaccination is not implemented.
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The cELISA technique developped at CIRAD (1) was adapted to a new format in collaboration
with IDEXX Montpellier SA. This allowed the production of a kit batch with precoated plates
whose thermostability was evaluated. A reference CCPP vaccine batch was produced at
CIRAD. It adhered to OIE guidelines and contained 0.15mg of purified Mccp antigen and 3mg
of saponin. The sero-conversion ellicited by this vaccine was first tested at CIRAD and then at
the AU-PANVAC. Goat sera were collected in France, Kenya and Ethiopia. In France, which is
CCPP free, they originated from goat herds that had been affected by mycoplasmas belonging
to the « mycoides cluster » but not by Mccp. In Kenya and Ethiopia, sera originated from
regions where CCPP was known to be enzootic but where no vaccination had been
implemented.
Specificity of the test: 478 sera from French origin had titers
ranging from -20 to 57% of inhibition. The distribution of these titers
was Gaussian . The cut-off value was established at 55% of inhibition
to ensure a very high specificity (99%) for the test. As CIRAD is
adhering to ISO17025 guidelines, an internal reference serum with a
titer around this cut-off was produced . This serum was used to
evaluate the uncertainty of measurement for this test at CIRAD
around the cut-off: +/- 8%.
Detectability: Out of 1000 sera collected in Ethiopia, 104 were
positive with titers ranging from 63% to 97% of inhibition . In
addtion, 43 sera had titers above 55% but were considered as
dubious because of the uncertainty of measurement. These
results establish the CCPP sero-prevalence in this Ethiopian
region between 10 and 15% and confirm that CCPP has a real
impact for the livelhood of nomadic herdsmen in the Afar region.
Post-vaccinal sero-conversion: Goats that were vaccinated with
a reference CCPP vaccine batch presented a rapid sero-
conversion already noticeable one week post vaccination. The
titers reached their maximum three weeks post-vaccination,
ranging from 73 to 93% of inhibition. These titers remained stable
for at least 5 weeks. By comparison, animals vaccinated with
vaccines containing lower quantities of antigen or adjuvant had
either lower titers or titers that were waning more rapidly.
Conclusions
-This cELISA CCPP kit has now been validated.
-As it detects a post-vaccinal sero-conversion it can be
used either to evaluate the quality of CCPP vaccine
batches or the quality of a vaccination campaigns.
-As it is strictly specific it can be used in countries that
do not vaccinate against CCPP to measure the
prevalence of the disease.
-The test should also be very helpful for the
surveillance of the disease in regions or countries that
are supposedly free but which border CCPP infected
zones.
